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Abstract  Oxidative stress (OXS) has been recently considered as one of anticancer strategies by taking advantage 
of higher vulnerability of cancer cells (than normal cells) to OXS. In fact, the successful outcomes using OXS have 
been reported in several cancer cases. A medicinal mushroom extract, PE isolated from Poria mushroom, has been 
shown to have anticancer/antitumor activity, although its anticancer mechanism has not been fully understood but 
may involve OXS. We investigated if PE might have anticancer effect on human bladder cancer cells through OXS 
in vitro. A dose-dependent (0-200 µg/ml of PE) study was first performed to assess cell viability using MTT assay. 
PE led to a significant reduction in cell viability with the IC50 (50% inhibitory concentration) of 100 µg/ml. A 
possible anticancer role of OXS was then assessed by lipid peroxidation (LPO) assay. The results indicated that PE 
indeed exerted ~2.1-fold greater OXS (than controls) on the cells. The anticancer mechanism of PE was further 
explored, focusing on glycolysis, metabolic signaling pathways, and apoptosis. Two glycolytic parameters, 
hexokinase (HK) activity and cellular ATP level, have significantly declined, suggesting the inhibition of glycolysis. 
Coupled with the reduced ATP level, AMP-activated protein kinase (AMPK) was activated, while protein kinase B 
(Akt) was inactivated and concomitantly mammalian target of rapamycin (mTOR) was inhibited. These results 
imply the growth cessation, followed by cell death. Western blot analysis also revealed that such cell death was more 
likely linked to apoptosis, indicated by the bcl-2 down-regulation and the Bax up-regulation. Therefore, PE is a 
natural anticancer agent with prooxidant activity exerting OXS, which leads to inhibition of glycolysis, modulations 
of metabolic signaling pathways, and ultimately apoptosis. It may have clinical implications in oral and/or 
intravesical administration for a safer and better therapeutic option for bladder cancer. 
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1. Introduction 
Bladder cancer is the second common urologic malignancy 
next to prostate cancer in the United States. Approximately 
79,000 new cases and nearly 17,000 deaths of patients 
with bladder cancer are estimated this year (2017) [1]. In 
males, bladder cancer represents the fourth most frequent 
diagnosis of new cancer annually [1]. Currently, transitional 
cell carcinoma (TCC) is the most prevalent type (~90%) 
of bladder cancers and approximately 80% of TCC present 
superficial bladder tumor while 15% are invasive and 5% 
are metastatic disease [2]. Unfortunately, regardless of 
non-muscle invasive or muscle invasive cases, the current 
treatment options are limited. For non-muscle invasive 
bladder cancer, endoscopic transurethral resection (TUR) 
is the primary modality with or without intravesical 
chemotherapy or immunotherapy. However, 60%-70% of 
patients will recur and ~25% will progress to muscle 
invasive disease within 5 years [3], becoming untreatable 
and fatal. For muscle invasive disease, chemotherapy and 
surgery are the two major modalities but the prognosis is 
less satisfactory because only 60% of these patients will 
survive five years later, due to distant recurrence [4]. 
Hence, it is crucial to establish the improved modalities to 
prevent multiple recurrences and progression to an advanced 
invasive disease. However, over the past several decades, 
only limited improvement or progress has been made. 
There is the urgent need for a more effective, safer 
treatment modality with few side effects. 
Recently, the medicinal aspects of various natural 
agents and substances have gained more public attention. 
Those include herbs, mushrooms, flowers, fruits, plant 
seeds, sea weeds, algae, tea, bark, shark cartilage and so 
on. We were particularly interested in one well-established 
medicinal mushroom called Poria mushroom and its 
bioactive extract, PE. This mushroom has been used in 
Traditional Chinese Medicine for 2,000 years [5] and 
found to have various properties, such as antioxidant, 
anticancer/antitumor, immunomodulatory, renoprotective 
effects etc. [6,7,8]. As PE is a natural agent, it is 
conceivable that it may have few side effects and clinical 
implications in cancer treatment. 
Oxidative stress (OXS), i.e. generation of reactive 
oxygen species (ROS), has been known to exert adverse 
effects on a variety of normal and cancer cells, injuring, 
damaging and even killing them [9]. ROS include superoxide 
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anion, singlet oxygen, hydroxyl radicals, hydrogen peroxide 
etc., which are commonly generated through incomplete 
reduction of molecular oxygen during aerobic metabolic 
processes [10]. Although OXS has never been appreciated 
by any means, it has been recently considered as one of 
anticancer strategies by taking advantage of cancer cells 
being more vulnerable to OXS than normal counterparts 
[11]. The exact reason for such higher vulnerability of 
cancer cells remains elusive, but at least it is believed to 
be the inherent difference in tissue-specific antioxidant 
system, i.e. the weakened or lack of antioxidant enzymes 
in cancer cells. As a matter of fact, the successful outcomes 
using OXS have been reported in several cancer cases 
[11,12,13]. 
Taking this OXS strategy into consideration, it was of 
our interest to study if PE could exert OXS on bladder 
cancer cells because PE may have not only antioxidant 
activity but also “prooxidant” activity (exerting OXS) like 
vitamin C [14]. If PE indeed exerts OXS, it could be the 
primary factor for its anticancer activity that has been 
demonstrated [6]. We also explored the OXS-mediated 
anticancer mechanism of PE, focusing on glycolysis,  
the status of metabolic signaling pathways, and possible 
induction of apoptosis. More details and interesting 
findings are described and discussed herein. 
2. Materials and Methods 
2.1. Cell Culture 
Human bladder cancer 5637 cells, obtained from the 
American Type Culture Collection (ATCC; Manassas, 
VA), were cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum, penicillin (100 U/ml), and 
streptomycin (100 µg/ml). Routinely, culture medium was 
changed every 3 to 4 days and the passage of cells was 
performed weekly. PE, the bioactive extract of Poria 
mushroom, was a generous gift from the manufacturer 
(Mushroom Wisdom, Inc., East Rutherford, NJ). For 
experiments, cells were seeded in the 6-well culture plate 
at the initial cell density of 2 x 105 cells/ml and cultured 
with varying concentrations of PE. Cell viability was 
determined at 72 h by MTT assay. 
2.2. MTT Assay (Cell Viability Test) 
Cell viability was determined by the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) 
assay following the vendor’s protocol (Sigma-Aldrich, St. 
Louis, MO). At the harvest time, MTT reagent (1 mg/ml) 
was added to each well in the 6-well plate, followed by  
3-h incubation at 37 °C. After discarding MTT reagent, 
dimethyl sulfoxide (1 ml each) was added to the plate to 
dissolve formazan precipitates formed. Formazan solution 
(purple) was read at 595 nm on a microplate reader. Cell 
viability was then expressed by the percent (%) of viable 
cells relative to the control reading (100%). 
2.3. Lipid Peroxidation (LPO) Assay 
The severity of oxidative stress can be assessed by LPO 
assay, which measures the amount of malondialdehyde  
(MDA) formed, due to damage in the plasma membrane 
under oxidative stress [15]. This indicates - the more  
MDA formed, the greater oxidative stress. The detailed 
procedures were described in the vendor’s protocol 
(ABCAM, Cambridge, MA). The amount of MDA formed 
was determined from the MDA standards and expressed 
by µM. 
2.4. Assays for Glycolytic Parameters 
To assess possible effects of PE on glycolysis, two 
glycolytic parameters, hexokinase (HK) activity and 
cellular ATP level, were determined using the HK or ATP 
Colorimetric Assay Kits (BioVision, Milpitas, CA), 
respectively, following the manufacturer’s protocols. 
HK Assay: Control or agents-treated cells were lysed in 
HK buffer provided and supernatant (cell lysates) was 
obtained by centrifugation. The NADH standards and cell 
lysates (20 µg per sample) were prepared in the 96-well 
plate and the reaction was started by the addition of 
reaction mix (containing substrate). Immediately the plate 
was placed in a microplate reader and the absorbance (OD) 
changes with time were monitored at 450 nm for 20 min 
with 5-min intervals. All readings were calculated and 
normalized and then HK activity was expressed by the % 
of sample activity relative to the controls (100%).  
ATP Assay: Cells (2 x 105 cells/ml) in the 6-well plate 
were first lysed in ATP assay buffer and cell lysates were 
deproteinized with HClO4 (perchloric acid) and 
neutralized with KOH (potassium hydroxide). The ATP 
standards and samples (50 µl per sample) were prepared in 
the 96-well plate and the reaction was started by the 
addition of reaction mixture. The plate was incubated at 
room temperature for 30 min in the dark. Absorbance (OD) 
at 570 nm was read on a microplate reader and ATP 
content was calculated by applying the sample readings to 
the ATP standards. The ATP level was then expressed by 
the % of sample readings relative to the controls (100%). 
2.5. Western Blot Analysis 
An equal amount of cell lysates (10 µg), obtained from 
control and agent-treated cells, was first subjected to 10% 
SDS gel electrophoresis and transferred to a nitrocellulose 
membrane (blot). The blot was first incubated for 90 min 
with the primary antibodies against three metabolic 
regulators, p-AMPK, p-Akt, and p-mTOR (Santa Cruz 
Biotechnology, Santa Cruz, CA), or with two apoptotic 
regulators, bcl-2 and Bax (Santa Cruz Biotechnology). 
After removing the primary antibodies, the blot was 
incubated with the secondary antibody conjugates for 30 
min. The specific immunoreactive protein bands were then 
detected by chemiluminescence following the manufacturer’s 
protocol (Kirkegaard and Perry Laboratories, Gaithersberg, 
MD). 
2.6. Statistical Analysis 
All data were presented as mean ± SD (standard 
deviation), and statistical differences between groups are 
assessed with either the unpaired Student’s t test or one-
way ANOVA analysis. Values of p <0.05 are considered 
to indicate statistical significance. 
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3. Results 
3.1. Effects of PE on Cell Viability of Bladder 
Cancer 5637 Cells 
To assess anticancer effect of PE on 5637 cells, cell 
viability, i.e. the % of viable cells, was determined after 
they were treated with varying concentrations (0-200 µg/ml) 
of PE for 72 h using MTT assay. Although PE at 50 μg/ml 
had little effect, it led to a ~50% and ~90% reduction  
in cell viability at 100 and 200 µg/ml, respectively, in a 
dose-dependent manner (Figure 1). Thus, PE appears to 
have anticancer effect, capable of significantly reducing 
5637 cell viability. As PE (100 μg/ml) is proximate to its 
IC50 (50% inhibitory concentration), this concentration 
was then used in the rest of our study. 
 
Figure 1. Dose-dependent effect of PE on cell viability. 5637 cells were 
cultured with varying concentrations of PE (0-200 µg/ml) and cell 
viability was assessed in 72 h by MTT assay. Cell viability was 
expressed by the percent (%) of viable cells relative to controls (100%). 
The data are mean ± SD (standard deviation) from three separate 
experiments (*p <0.05 compared with control) 
3.2. Exertion of Oxidative Stress (OXS) by PE 
Whether PE-induced cell viability reduction could be 
due to OXS was examined next. Hydrogen peroxide 
(H2O2, 50 µM), one of typical ROS, was also used as a 
positive control for exerting OXS on cells. As OXS 
usually takes place at the early phase, after cells were 
briefly exposed to PE (100 µg/ml) or H2O2 (50 µM) for 3 
or 6 h, they were subjected to LPO assay to determine the 
severity of OXS. Compared to controls, H2O2 and PE led 
to a ~3.2-fold and ~2.1-fold increase in the MDA amounts 
at 6 hours, respectively (Figure 2). Thus, PE (as well as 
H2O2) appears to be capable of exerting severe OXS on 
5637 cells, demonstrating its prooxidant activity and 
presumably accounting for the significant cell viability 
reduction (Figure 1). 
 
Figure 2. Assessment of severity of OXS. Cells were exposed to PE 
(100 µg/ml) or H2O2 (50 µM) for 3 or 6 h, and the amount of MDA 
formed (µM)) was assessed by LPO assay. All data are mean ± SD from 
three independent experiments (*p <0.05 compared with controls) 
 
Figure 3. Inhibition of glycolysis by PE. Cells were treated with PE (100 
µg/ml) for 72 h and subjected to HK and ATP assays separately. HK 
activity and ATP level are expressed by the % relative to respective 
controls (100%). The data are mean from three separate experiments (*p 
<0.05 compared with control) 
3.3. Effect of PE-Exerted OXS on Glycolysis 
To have an insight into how PE-exerted OXS would 
induce a significant cell viability reduction or to understand 
the anticancer mechanism of PE, we first examined if 
glycolysis could be affected/inhibited by PE because it is 
the vital metabolic process required for cell proliferation 
and survival [16,17]. We specifically focused on one of 
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key glycolytic enzymes, hexokinase (HK), which was 
involved in the irreversible committed step in glycolysis 
[18]. Assuming that HK was inhibited by PE, the amount 
of ATP produced or the cellular ATP level would also 
decline because the sequential glycolytic pathway could 
not be even initiated and completed. Accordingly, cells 
were treated with PE (100 µg/ml) for 72 h and HK activity 
and ATP level were assessed, as described in Materials 
and Methods. Compared to controls (100%), HK activity 
declined to ~50% (i.e. a ~50% activity loss) with PE 
treatment (Figure 3). ATP assay revealed that the cellular 
ATP level was also down to ~45% (i.e. a ~55% reduction), 
due to HK inactivation. Thus, the reduction in HK and 
ATP levels by PE indicates the inhibition of glycolysis, 
eventually leading to the growth cessation and the cell 
viability reduction. 
3.4. Effects of OXS on Metabolic Signaling 
Pathways 
ATP (energy) reduction/depletion, due to the glycolysis 
inhibition, has been shown to affect metabolic signaling 
pathways, which play a pivotal role in cell proliferation 
and survival [17,19]. The cells treated with/without PE for 
72 h were analyzed for three key regulators, AMP-activated 
protein kinase (AMPK) [20], serine/threonine protein 
kinase B (Akt) [21], or mammalian target of rapamycin 
(mTOR) [22] by Western blots. Such analysis revealed 
that the expression of AMPK was enhanced or phosphorylated 
(activated), whereas those of Akt and mTOR were 
reduced or dephosphorylated (inactivated) with PE 
treatment (Figure 4). Therefore, this activation of AMPK 
concomitant with inactivation of Akt/mTOR by PE 
suggests that 5637 cells more likely undergo cell death as 
it has been shown in certain cancer cells [20,21,22]. 
 
Figure 4. Modulations of metabolic regulators by PE. Cells treated with 
PE (100 µg/ml) for 72 h were analyzed for three key metabolic 
regulators using Western blots. Autoradiographs of p-AMPK, p-Akt, and 
p-mTOR expressed in control and PE-treated cells are shown for 
comparison. Beta-actin is also shown as a loading control 
3.5. Possible Induction of Apoptosis by PE 
As it seems that the cell viability reduction by PE could 
be primarily due to cell death, we next examined if such 
cell death would be linked to apoptosis. The cells treated 
with/without PE for 72 h were analyzed for two key 
apoptotic regulators by Western blots. Such analysis 
showed that PE treatment led to the down-regulation 
(reduced expression) of anti-apoptotic bcl-2 and the up-
regulation (elevated expression) of pro-apoptotic Bax 
(Figure 5). Such modulations of two regulators will  
favor and indicate induction of apoptosis [23]. It is thus 
plausible that PE-induced cell death would be rather 
linked to apoptosis. 
 
Figure 5. Induction of apoptosis. Autoradiographs of two apoptotic 
regulators, bcl-2 and Bax, expressed in control and PE-treated cells are 
shown following Western blot analysis 
4. Discussion 
Because of the ineffective therapeutic options and 
unsatisfactory outcomes, bladder cancer patients and their 
families are desperately seeking for a better, more effective 
therapeutic modality. We have been exploring an alternative 
or unconventional way to improve the therapeutic efficacy 
using natural substances or products. We have come 
across the bioactive mushroom extract, PE, isolated from 
Poria mushroom and investigated if it might have 
anticancer effect on human bladder cancer cells.  
PE had a significant anticancer effect with the IC50 of 
~100 μg/ml on bladder cancer 5637 cells (Figure 1). To 
explore its anticancer mechanism, we examined if it  
could be associated with oxidative stress (OXS). LPO 
assay showed that PE did exert severe OXS on 5637 cells 
as indicated by a ~2-fold increase in MDA formation (Figure 
2). This finding suggests that anticancer mechanism of PE 
would be substantially attributed to OXS. It has been well 
known that OXS was harmful to both normal and cancer 
cells but particularly cancer cells were highly or more 
vulnerable to OXS [11]. Although the reason for such 
discrepancy remains to be elucidated, the inherent 
difference in tissue-specific antioxidant system is believed 
to at least in part account for it. Based on this uncanny 
nature of cancer cells, OXS is now considered as one of 
anticancer strategies. Suppose relatively weak OXS were 
exerted on normal and cancer cells, it could be yet severe 
or strong enough to kill cancer cells (due to weaker 
antioxidant enzymes) but not severe enough to even injure 
normal cells (with stronger enzymes). More studies on the 
status of antioxidant enzymes in bladder cancer need to be 
further conducted. 
Nevertheless, to elucidate how PE-exerted OXS would 
lead to the cell viability reduction or even cell death, we 
examined its effect on glycolysis, an essential metabolic 
process. Such study showed that HK was specifically 
targeted and inactivated by OXS, shutting down the 
glycolytic pathway. As a result, ATP synthesis was  
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also halted and its cellular level significantly declined. 
These results indicate the inhibition of glycolysis and  
cells may subsequently cease cell growth and result in cell 
death. 
As it has been shown that ATP depletion (due to the 
glycolysis inhibition) would also influence metabolic 
signaling pathways [17], this possibility was tested. We 
found that the three key signaling regulators, AMPK, Akt, 
and mTOR [20,21,22], were modulated by PE (Figure 4). 
In fact, AMPK was highly phosphorylated (activated) 
while Akt was dephosphorylated (inactivated) by PE. 
Both AMPK and Akt must be phopsphrylated to become 
active and functional [20,21]. Activation of AMPK has 
been shown to be cytotoxic to a variety of cancer cells and 
promote apoptosis [24], while Akt activation would 
promote cell survival by inhibiting apoptosis [21,25]. 
Hence, AMPK and Akt will interact directly through two 
opposed mechanisms [20], and activation or inhibition of 
these two parameters would determine an anabolic or 
catabolic process. In addition, activation of AMPK and 
inhibition of Akt (as seen in this study) is known to 
inactivate the master orchestrator of cell proliferation, 
mTOR, which is a protein kinase working with Akt to 
promote protein synthesis and cell proliferation [22]. This 
is consistent with our finding that mTOR (along with  
Akt) was indeed dephosphorylated or inactivated by PE 
(Figure 4). Thus, AMPK activation and Akt/mTOR 
inactivation induced by PE would ultimately lead to  
cell death, more likely accounting for the cell viability 
reduction. Lastly, whether such cell death induced by PE 
would be linked to apoptosis was examined. Western blot 
analysis revealed the down-regulation of bcl-2 and the  
up-regulation of Bax with PE treatment (Figure 5). As  
bcl-2 is anti-apoptotic but Bax is pro-apoptotic [23], this 
finding is rather in support of apoptosis. Thus, PE-induced 
cell death appears to follow apoptotic pathway. 
5. Conclusion  
In this study, PE demonstrated its anticancer activity on 
human bladder cancer 5637 cells in vitro. Such anticancer 
activity appears to be primarily attributed to OXS, which 
leads to inhibition of glycolysis, modulation of metabolic 
signaling pathways, and ultimate induction of apoptosis. 
As a result, cell viability will significantly decline 
following PE treatment. Therefore, PE with prooxidant 
activity exerting OXS could be a promising natural 
anticancer agent that may offer a safer and more effective 
therapeutic option for bladder cancer. 
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